样式: 排序: IF: - GO 导出 标记为已读
-
Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-21 Rand Abedalweli, Michelle Nguyen, Atul Deodhar
The advent of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have transformed the management of immune-mediated rheumatic diseases, including spondylarthritis (...
-
What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes? Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-21 Abdo Meyiah, Eyad Elkord
Forkhead box P3 (FoxP3) transcription factor plays critical roles in controlling immune responses and cancer progression in different cancers. FoxP3 expression within the tumor microenvironment (TM...
-
How to and should we target EBV in MS? Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-13 Svetlana Eckert, Dejan Jakimovski, Robert Zivadinov, Mark Hicar, Bianca Weinstock-Guttman
The etiology of multiple sclerosis (MS) remains unknown. Pathogenesis likely relies on a complex interaction between multiple environmental, genetic, and behavioral risk factors. However, a growing...
-
Preventing fibrosis in IBD: update on immune pathways and clinical strategies Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-12 Jie Wang, Bo Yang, Jyotsna Chandra, Andrei Ivanov, J. Mark Brown, Florian Rieder
Intestinal fibrosis is a common and serious complication of inflammatory bowel diseases (IBD) driving stricture formation in Crohn’s disease patients and leading to submucosal damage in ulcerative ...
-
Re-evaluation of nailfold capillaroscopy in discriminating primary from secondary Raynaud’s phenomenon and in predicting systemic sclerosis: a randomised observational prospective cohort study Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-11 Marta C. Amaral, F Seguro Paula, Joana Caetano, Paul RJ Ames, J Delgado Alves
Primary Raynaud’s phenomenon (pRP) is difficult to distinguish from secondary (sRP). Although nailfold capillaroscopy (NFC) may detect early alterations, no universal criteria yet discriminate betw...
-
Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-08 Haoyi Zou, Chao Liu, Yuli Ruan, Lin Fang, Tong Wu, Shuling Han, Tianjiao Dang, Hongxue Meng, Yanqiao Zhang
Different pathological types of colorectal cancer have distinguished immune landscape, and the efficacy of immunotherapy will be completely different. Colorectal medullary carcinoma, accounting for...
-
Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-04 Morgan L. Agner, Shirley P. Parraga, Zina M. Arkhipenko, Rita O. Pichardo, Amy J. McMichael, Steven R. Feldman
Published in Expert Review of Clinical Immunology (Just accepted, 2024)
-
Antiphospholipid antibodies and the risk of adverse pregnancy outcomes in patients with systemic lupus erythematosus: a systematic review and meta-analysis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-06 Jinge Huang, Qingmiao Zhu, Baizhou Wang, Hanzheng Wang, Zhijun Xie, Xingyu Zhu, Ting Zhao, Zi Yang
This article aims to evaluate the magnitude of adverse pregnancy outcomes (APOs) risks associated with different antiphospholipid antibody (aPL) profiles in women with systemic lupus erythematosus ...
-
Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-06 Francesco Reggiani, Matteo Stella, Marta Calatroni, Renato Alberto Sinico
ANCA-associated vasculitides (AAV), classified into granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis represent a group of disorders char...
-
Current approaches for diagnosis of subclinical pulmonary tuberculosis, clinical implications and future perspectives: a scoping review Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-05 Shima Mahmoudi, Maria J García, Paul K Drain
Subclinical tuberculosis (TB) is the presence of TB disease among people who are either asymptomatic or have minimal symptoms.Currently, there are no accurate diagnostic tools and clear treatment a...
-
Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-04 Kelly Hawkins, Eden David, Jacob W Glickman, Ester Del Duca, Emma Guttman-Yassky, James G Krueger
Atopic dermatitis (AD) is a common, chronic inflammatory skin disorder driven by an intricate interplay of genetic, environmental, and immunological factors.As a clinically heterogenous condition, ...
-
Immunobiology and treatment of cutaneous T cell lymphoma Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-03-04 Rishi R. Goel, Alain H. Rook
Primary cutaneous T cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas derived from skin-homing T cells. These include mycosis fungoides and it’s leukemic variant Sezary syndro...
-
Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-02-26 Timothy Kaniecki, Michael Hughes, Zsuzsanna McMahan
Systemic sclerosis (SSc) is a connective tissue disease with heterogeneous presentation. Gastrointestinal (GI) complications of SSc are characterized by esophageal reflux, abnormal motility, and mi...
-
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-02-24 Noha Abdel-Wahab, Maria E. Suarez-Almazor
The advent of immune checkpoint inhibitors (ICIs) in cancer treatment has marked a transformative era, albeit tempered by immune-related adverse events (irAEs), including those impacting the muscul...
-
Recent insights into extracorporeal photopheresis for graft-versus-host disease Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-02-20 Claudia Del Fante, Cesare Perotti
Extracorporeal Photopheresis (ECP) may be considered the unique large-scale cell therapy currently available. It is currently employed mainly as second-line treatment, especially in steroid-resista...
-
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-02-16 Howard Trachtman, Radko Komers, Jula Inrig
IgA nephropathy is one of the most common forms of glomerular disease. Patients with persistent proteinuria are at increased risk of progression to kidney failure. There is a significant need for s...
-
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-02-07 Christophe Dupont, A.Wesley Burks, David M. Fleischer, Katharine J. Bee, Sarita Chainani, Hugh A. Sampson
DBV712 250 µg, (also referred to as Viaskin Peanut or peanut patch; Viaskin is a trademark of DBV Technologies), is an innovative approach to epicutaneous immunotherapy (EPIT). The patch-based tech...
-
Incidence of coronary artery lesions in children with recurrent Kawasaki disease Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-02-05 Xi Chen, Lu Gao, Zhen Zhen, Ying Wang, Jia Na, Wen Yu, Zhiyu Tian, Yue Yuan, Suyun Qian
Coronary artery lesions (CALs) are a major complication of Kawasaki disease (KD); however, data on CAL incidence and risk factors in recurrent KD are limited.Ninety-seven children with recurrent KD...
-
Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-02-01 Hanna Kim
Juvenile dermatomyositis (JDM) is a rare autoimmune disease most commonly with proximal weakness due to inflammation and characteristic skin rashes. Most patients have a chronic or polycyclic disea...
-
Correction Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-24
Published in Expert Review of Clinical Immunology (Vol. 20, No. 3, 2024)
-
Matrix metalloproteinases in chronic rhinosinusitis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-22 Yuqing Huang, Bing Yan, Chen Meng, Luo Zhang, Chengshuo Wang
Matrix metalloproteinases (MMPs) are a group of enzymes that are essential in maintaining extracellular matrix (ECM) homeostasis, regulating inflammation and tissue remodeling. In chronic rhinosinu...
-
Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Sho Fukui, Satoshi Kawaai, Haruki Sawada, Mitsumasa Kishimoto
Non-radiographic axial spondyloarthritis (nr-axSpA) is a chronic inflammatory condition with axial and peripheral musculoskeletal involvement, fulfilling criteria of axSpA in the absence of advance...
-
Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Valeria Dipasquale, Angela Alibrandi, Salvatore Pellegrino, Vincenzo Ramistella, Claudio Romano
The pharmacokinetics and pharmacodynamics of biosimilar infliximab (IFX-BioS) in pediatric inflammatory bowel disease (IBD) are poorly investigated. The aim of this study was to investigate factors...
-
At the cutting-edge: what’s the latest in imaging to diagnose Sjögren’s disease? Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 A. Vissink, MS. van Ginkel, H. Bootsma, AWJM. Glaudemans, K. Delli
Published in Expert Review of Clinical Immunology (Vol. 20, No. 2, 2024)
-
Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Nina Maria Fanaropoulou, Georgia C. Tsatsani, Theocharis Koufakis, Kalliopi Kotsa
Type 1 diabetes (T1D) is a chronic autoimmune endocrinopathy with increasing incidence that results in the depletion of pancreatic beta cells and exogenous insulin dependence. Despite technological...
-
A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Ecem Sevim, Dale Kobrin, Maria Casal-Dominguez, Iago Pinal-Fernandez
Dermatomyositis (DM) is a rare inflammatory disease with diverse cutaneous and systemic manifestations, often associated with myositis-specific antibodies. Managing patients with refractory DM, or ...
-
A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Amandeep Salhotra, Leah Falk, Gabriel Park, Karamjeet Sandhu, Haris Ali, Badri Modi, Susanta Hui, Ryotaro Nakamura
Patients with chronic graft versus host disease (cGVHD) have low circulating regulatory T cells (Tregs). Interleukin-2(IL-2) is a growth factor for Tregs, and clinical trials have explored its use ...
-
Pan-cancer analysis of the prognostic significance of ACKR2 expression and the related genetic/epigenetic dysregulations Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Hongxiu Dong, Shijie Zhou, Xuxi Chen, Xuejie Deng, Aiping Fang
ACKR2 is a scavenger for most inflammation-related CC chemokines. This study aimed to assess the pan-cancer prognostic significance of ACKR2 and the genetic and epigenetic mechanisms underlying its...
-
Bimekizumab for the treatment of psoriatic arthritis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Yoshiya Tanaka, Stevan Shaw
Interleukin (IL)-17A and IL-17F have overlapping roles in pro-inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease. Bimekizumab is the first human monoclonal ant...
-
Eosinophilic esophagitis: does age matter? Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-21 Sara Massironi, Alessandra Elvevi, Roberto Panceri, Giacomo Mulinacci, Giacomo Colella, Andrea Biondi, Pietro Invernizzi, Silvio Danese, Edoardo Vespa
Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus with increasing prevalence worldwide. It is a multifactorial disease caused by a combination of immunologic, geneti...
-
Comparison of high- and low-molecular-weight sensitizing agents causing occupational asthma: an evidence-based insight Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-18 Virginie Doyen, Denyse Gautrin, Olivier Vandenplas, Jean-Luc Malo
The many substances used at the workplace that can cause sensitizer-induced occupational asthma are conventionally categorized into high-molecular-weight (HMW) agents and low-molecular-weight (LMW)...
-
Why does malaise/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-15 Yoshiya Tanaka, Kei Ikeda, Yuko Kaneko, Naoki Ishiguro, Tsutomu Takeuchi
Fatigue and malaise are commonly associated with a wide range of medical conditions, including rheumatoid arthritis (RA). Evidence suggests that fatigue and malaise can be overwhelming for patients...
-
The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-15 Hai-Zhou Ji, Bin Liu, Mi Ren, Sang Li, Jianfeng Zheng, Tong-Yu Liu, Hui-Hui Yu, Yang Sun
This study aimed to check the expression profile of the C-X-C motif chemokine ligands (CXCLs)-C-X-C motif chemokine receptor 2 (CXCR2) axis in cervical cancer and to explore the cross-talk between ...
-
Pro-inflammatory cytokines in spondyloarthritis: a case-control study Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-11 Maroua SLOUMA, Lobna KHARRAT, Aymen TEZEGDENTI, Rim DHAHRI, Ezzeddine GHAZOUANI, Imen GHARSALLAH
We aimed to determine the discriminative values of pro-inflammatory cytokines to distinguish spondyloarthritis patients from healthy subjects and to assess the association between these cytokines a...
-
A critical evaluation of nemolizumab for prurigo nodularis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-13 Sarah G Brooks, Gil Yosipovitch
Prurigo nodularis (PN) is a chronic inflammatory skin condition that presents with intensely pruritic, hyperkeratotic nodules. The pathophysiology underlying PN is not entirely clear, making treatm...
-
The role of immune reconstitution in relapse after allogeneic hematopoietic stem cell transplantation Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-10 Xu-Ying Pei, Xiao-Jun Huang
Leukemia relapse following stem cell transplantation remains a significant barrier to long-term remission. Timely and balanced immune recovery after transplantation is crucial for preventing leukem...
-
Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: lessons from treatment in adults and the way forward Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Narendra Kumar Bagri, Hayley King, A. V. Ramanan
Targeting IL-17A using Secukinumab; a humanized monoclonal immunoglobulin G1 (IgG1)/κ against IL-17A is a therapeutic option for immune-mediated disorders such as psoriasis and ankylosing spondylit...
-
Considerations for managing elderly patients with atopic dermatitis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-09 Maddalena Napolitano, Luca Potestio, Mariateresa Nocerino, Cataldo Patruno
Atopic dermatitis (AD) diagnosis in elderly is challenging, due to its clinical polymorphism and the lack of diagnostic biomarkers. Moreover, the chronicity of the disease and the complex pathogene...
-
Intravenous difelikefalin for the treatment of hemodialysis pruritus Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Rami H. Mahmoud, Omar Mahmoud, Gil Yosipovitch
Patients with chronic kidney disease (CKD) undergoing hemodialysis often experience significant itch secondary to their condition and a subsequent reduction in their overall quality of life. Curren...
-
Pediatric IgG4-related disease: a descriptive review Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Satoshi Hara, Misaki Yoshida, Hajime Sanada, Yasunori Suzuki, Yasuharu Sato, Ichiro Mizushima, Mitsuhiro Kawano
IgG4-related disease (IgG4-RD) is an immune-mediated systemic fibroinflammatory condition characterized by serum IgG4 elevation and IgG4-positive plasma cell infiltration into various organs. It ge...
-
Hematological involvement in sarcoidosis: from cytopenias to lymphoma Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Pilar Brito-Zerón, Elyse E. Lower, Manuel Ramos-Casals, Robert P. Baughman
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignanci...
-
Rheumatic masqueraders: mimics of primary vasculitis - a case-based review Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Matthew J. Koster, Max Guarda, Umar Ghaffar, Kenneth J. Warrington
Vasculitis conditions are often serious and sometimes fatal diseases, therefore it is paramount to diagnose correctly and treat appropriately. Mimics of primary vasculitis can include either non-in...
-
Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis – a meta-analysis of randomized clinical trials Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Monika Marko, Rafał Pawliczak
Atopic dermatitis (AD) increases the risk of bacterial and viral cutaneous infections. This study assesses the risk of skin infections related to dupilumab monotherapy in moderate-to-severe AD.We s...
-
Evaluation and management of dry mouth and its complications in rheumatology practice Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Zohreh Khavandgar, Blake M. Warner, Alan N. Baer
The symptom of dry mouth has multiple potential etiologies and can be a diagnostic clue to the presence of common systemic diseases encountered in rheumatology practice. The presence of decreased s...
-
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-08 Noémie Gensous, Estibaliz Lazaro, Patrick Blanco, Christophe Richez
Type 1 interferons (IFNs) play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE) and various type I IFNs targeting therapeutic approaches have been developed. Anifrolumab, a ...
-
Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022 Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-02 Ivan Foeldvari, Kathryn S. Torok, Jordi Antón, Michael Blakley, Tamás Constantin, Maurizio Cutolo, Christopher P. Denton, Kim Fligelstone, Bernd Hinrichs, Suzanne C. Li, Susan Maillard, Edoardo Marrani, Pia Moinzadeh, Catherine H. Orteu, Clare E. Pain, John D. Pauling, Clarissa Pilkington, Franziska Rosser, Vanessa Smith, Daniel F. Furst
Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently there is only one consensus treatment guideline concerning skin, pulmonary and vascul...
-
A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2024-01-01 Elisa Pignatti, Monia Maccaferri, Alessandra Pisciotta, Gianluca Carnevale, Carlo Salvarani
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease with systemic manifestations. Although the success of immune modulatory drug therapy is considerable, about 40% of patients do...
-
Upadacitinib for the treatment of adult patients with active psoriatic arthritis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-28 Antonio Marchesoni, Giorgia Citriniti, Nicolò Girolimetto, Niccolò Possemato, Carlo Salvarani
Psoriatic arthritis (PsA) is a rheumatic disorder that may be responsible for relevant articular impairment. The recently licensed Janus Kinase (JaK) inhibitors represent a new opportunity to impro...
-
The pathophysiology of MASLD: an immunometabolic perspective Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-27 Julian Schwärzler, Felix Grabherr, Christoph Grander, Timon E. Adolph, Herbert Tilg
Metabolic-associated liver diseases have emerged pandemically across the globe and are clinically related to metabolic disorders such as obesity and type 2 diabetes. The new nomenclature and defini...
-
Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-25 Diana Paredes-Ruiz, Daniel Martin-Iglesias, Guillermo Ruiz-Irastorza
Hydroxychloroquine (HCQ) and glucocorticoids (GCs) constitute the oldest and more used drugs in the treatment of systemic lupus erythematosus (SLE). Despite this long experience, both are still sub...
-
Patch testing while immunosuppressed: potential risks and benefits Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-23 Mykayla Sandler, JiaDe Yu
Allergic contact dermatitis (ACD) is a common cutaneous inflammatory skin disorder that is diagnosed via epicutaneous patch testing (PT). ACD may also coexist with other systemic inflammatory condi...
-
The clinical role of Anakinra in the armamentarium against familial mediterranean fever Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-22 Kerem Parlar, Muhammed Bahaddin Ates, Bugra Han Egeli, Serdal Ugurlu
Familial Mediterranean Fever (FMF) is the most common autoinflammatory disease that has mainly been treated with colchicine since 1972. A significant portion of patients do not respond to colchicin...
-
Biologics for hidradenitis suppurativa: evolution of the treatment paradigm Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-22 Carlo Alberto Maronese, Chiara Moltrasio, Giovanni Genovese, Angelo Valerio Marzano
Hidradenitis suppurativa (HS) is an autoinflammatory skin disease with a high unmet need for effective medical management. Clinically, it is characterized by inflammatory nodules that may progress ...
-
Tapinarof cream for the topical treatment of plaque psoriasis in adults Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-20 Kaley Prieto, Jessica Q. Duong, Steven R. Feldman
Plaque psoriasis, a chronic immune-mediated skin disorder, is characterized by well-demarcated erythematous plaques with silvery scales. This condition stems from complex interactions between genet...
-
A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-19 Philippe Devillier, Mathieu Molimard, Jean-François Bergmann, Bertrand Delaisi, Amandine Gouverneur, Jade Vadel, Cédric Collin, Laurence Girard, Silvia Scurati, Pascal Demoly
The only causal treatment for allergic rhinitis (AR) is allergen immunotherapy (AIT) including personalized liquid sublingual AIT (SLIT). We present the methodology for establishing the EfficAPSI c...
-
Causal role of immune cells in chronic obstructive pulmonary disease: Mendelian randomization study Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-19 Bi Ran, Jiangyue Qin, Yanqiu Wu, Fuqiang Wen
Innate and adaptive immunity play different roles in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, previous studies on the relationship between immune cells and COPD re...
-
The complex relationship between large granular lymphocyte leukemia and rheumatic disease Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-18 Tony Marchand, Thierry Lamy
Large granular lymphocytic (LGL) leukemia is a rare lymphoproliferative disorder characterized by an expansion of clonal T or NK lymphocytes. Neutropenia-related infections represent the main clini...
-
Managing acute COVID-19 in immunocompromised pediatric patients Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-18 Federico Mercolini, Nicoletta Abram, Simone Cesaro
SARS-CoV-2 infection is a potentially life-threatening infection in immunocompromised pediatric patients, and its management has rapidly evolved during the pandemic. To control SARS-CoV-2 infection...
-
Role of CD68 in the tumor immune microenvironment in Hodgkin’s lymphoma Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-12 Valeria Tomarchio, Luigi Rigacci
Despite the high rate of cure in classical Hodgkin Lymphoma (cHL), some patients experienced a refractory disease, sometimes, hardly curable. In the pathogenesis of cHL, Reed Sternberg Cells (HRSC)...
-
Management and treatment optimization of patients with mild to moderate ulcerative colitis Expert Rev. Clin. Immunol. (IF 4.4) Pub Date : 2023-12-12 Ferdinando D’Amico, Ernesto Fasulo, Vipul Jairath, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a significant health-care burden worldwide. While medical therapy aims to induce and maintain remission, optimal management of m...